Protection of the human gut microbiome from antibiotics

Journal of Infectious Diseases

Volumn 217, Issue 4, 2018, Pages 628-636

  De Gunzburg, Jean ^a   Ghozlane, Amine ^b   Ducher, Annie ^a   Le Chatelier, Emmanuelle ^b   Duval, Xavier ^c,d,e   Ruppé, Etienne ^b,e,f,g   Armand Lefevre, Laurence ^c,d,e   Sablier Gallis, Frédérique ^a   Burdet, Charles ^d,e   Alavoine, Loubna ^c   Chachaty, Elisabeth ^f   Augustin, Violaine ^a   Varastet, Marina ^a   Levenez, Florence ^b   Kennedy, Sean ^b,e,h   Pons, Nicolas ^b   Mentré, France ^d,e   Andremont, Antoine ^c,d,e  

^a Da Volterra   (France)

^b University of Paris Saclay   (France)

^c BICHAT HOSPITAL   (France)

^d INSERM   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

^f INSTITUT GUSTAVE ROUSSY   (France)

^g UNIVERSITÉ PARIS DIDEROT   (France)

^h INSTITUT PASTEUR   (France)

Author keywords

Antibiotics; Clostridium difficile; Fluoroquinolones; Microbiome

Indexed keywords

ANTIBIOTIC AGENT; DAV 132; MOXIFLOXACIN; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; CHARCOAL;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ADSORPTION; DRUG EFFECT; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; EX VIVO STUDY; FECES ANALYSIS; FEMALE; FOLLOW UP; HUMAN; HUMAN EXPERIMENT; INTESTINE FLORA; MALE; MAXIMUM CONCENTRATION; METAGENOMICS; NORMAL HUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; SPECIES COMPOSITION; SPECIES RICHNESS; AGED; CHEMISTRY; FECES; MICROBIOLOGY; MICROFLORA; MIDDLE AGED; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CHARCOAL; FECES; FEMALE; GASTROINTESTINAL MICROBIOME; HEALTHY VOLUNTEERS; HUMANS; MALE; METAGENOMICS; MICROBIOTA; MIDDLE AGED; MOXIFLOXACIN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85044472999     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jix604     Document Type: Article

References (33)

1. Jernberg C, Lofmark S, Edlund C, Jansson JK. Long-term impacts of antibiotic exposure on the human intestinal microbiota. Microbiology 2010;156:3216-23.
2. Dethlefsen L, Relman DA. Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation. Proc Natl Acad Sci U S A 2011;108(Suppl 1):4554-61.
3. Perez-Cobas AE, Gosalbes MJ, Friedrichs A, et al. Gut microbiota disturbance during antibiotic therapy: a multiomic approach. Gut 2013;62:1591-601.
4. Belkaid Y, Hand TW. Role of the microbiota in immunity and inflammation. Cell 2014;157:121-41.
5. Cox LM, Blaser MJ. Antibiotics in early life and obesity. Nat Rev Endocrinol 2015;11:182-90.
6. de Lastours V, Fantin B. Resistance to fluoroquinolones in 2010: what are the consequences for prescriptions in intensive care units? Reanimation 2010;19:347-53.
7. Johanesen PA, Mackin KE, Hutton ML, et al. Disruption of the gut microbiome: Clostridium difficile infection and the threat of antibiotic resistance. Genes (Basel) 2015;6:1347-60.
8. Leffler DA, Lamont JT. Clostridium difficile infection. N Engl J Med 2015;372:1539-48.
9. Brown KA, Khanafer N, Daneman N, Fisman DN. Metaanalysis of antibiotics and the risk of community-associated Clostridium difficile infection. Antimicrob Agents Chemother 2013;57:2326-32.
10. Deshpande A, Pasupuleti V, Thota P, et al. Communityassociated Clostridium difficile infection and antibiotics: a meta-analysis. J Antimicrob Chemother 2013;68:1951-61.
11. Slimings C, Riley TV. Antibiotics and hospital-acquired Clostridium difficile infection: update of systematic review and meta-analysis. J Antimicrob Chemother 2014;69:881-91.
12. Lynch SV, Pedersen O. The human intestinal microbiome in health and disease. N Engl J Med 2016;375:2369-79.
13. Pedersen HK, Gudmundsdottir V, Nielsen HB, et al.; MetaHIT Consortium. Human gut microbes impact host serum metabolome and insulin sensitivity. Nature 2016;535:376-81.
14. Cox LM, Yamanishi S, Sohn J, et al. Altering the intestinal microbiota during a critical developmental window has lasting metabolic consequences. Cell 2014;158:705-21.
15. Le Chatelier E, Nielsen T, Qin J, et al.; MetaHIT Consortium. Richness of human gut microbiome correlates with metabolic markers. Nature 2013;500:541-6.
16. Leonard F, Andremont A, Leclerq B, Labia R, Tancrede C. Use of beta-lactamase-producing anaerobes to prevent ceftriaxone from degrading intestinal resistance to colonization. J Infect Dis 1989;160:274-80.
17. Stiefel U, Pultz NJ, Harmoinen J, et al. Oral administration of beta-lactamase preserves colonization resistance of piperacillin- treated mice. J Infect Dis 2003;188:1605-9.
18. Stiefel U, Nerandzic MM, Koski P, Donskey CJ. Orally administered beta-lactamase enzymes represent a novel strategy to prevent colonization by Clostridium difficile. J Antimicrob Chemother 2008;62:1105-8.
19. Pitout JDD. IPSAT P1A, a class A beta-lactamase therapy for the prevention of penicillin-induced disruption to the intestinal microflora. Curr Opin Investig Drugs Lond Engl 2000 2009;10:838-44.
20. Connelly S, Bristol JA, Hubert S, et al. SYN-004 (ribaxamase), an oral beta-lactamase, mitigates antibiotic-mediated dysbiosis in a porcine gut microbiome model. J Appl Microbiol 2017. http://www.pubmed.org/28245091. Accessed 28 February 2017.
21. Khoder M, Tsapis N, Domergue-Dupont V, Gueutin C, Fattal E. Removal of residual colonic ciprofloxacin in the rat by activated charcoal entrapped within zinc-pectinate beads. Eur J Pharm Sci 2010;41:281-8.
22. de Gunzburg J, Ducher A, Modess C, et al. Targeted adsorption of molecules in the colon with the novel adsorbent- based medicinal product, DAV132: a proof of concept study in healthy subjects. J Clin Pharmacol 2015;55:10-6.
23. Edlund C, Beyer G, Hiemer-Bau M, Ziege S, Lode H, Nord CE. Comparative effects of moxifloxacin and clarithromycin on the normal intestinal microflora. Scand J Infect Dis 2000;32:81-5.
24. Godon JJ, Zumstein E, Dabert P, Habouzit F, Moletta R. Molecular microbial diversity of an anaerobic digestor as determined by small-subunit rDNA sequence analysis. Appl Environ Microbiol 1997;63:2802-13.
25. Suau A, Bonnet R, Sutren M, et al. Direct analysis of genes encoding 16S rRNA from complex communities reveals many novel molecular species within the human gut. Appl Environ Microbiol 1999;65:4799-807.
26. Nielsen HB, Almeida M, Juncker AS, et al.; MetaHIT Consortium; MetaHIT Consortium. Identification and assembly of genomes and genetic elements in complex metagenomic samples without using reference genomes. Nat Biotechnol 2014;32:822-8.
27. Cotillard A, Kennedy SP, Kong LC, et al.; ANR MicroObes consortium. Dietary intervention impact on gut microbial gene richness. Nature 2013;500:585-8.
28. Langmead B. Aligning short sequencing reads with Bowtie. Curr Protoc Bioinforma 2010. doi:10.1002/0471250953. bi1107s32.
29. Kitzis MD. Antibiotic assay. Antibiogram. Courvalin P, Leclerc R, Rice LB. Portland, OR: ESKA Publishing, ASM Press, 2010.
30. Stass H, Kubitza D, Moller JG, Delesen H. Influence of activated charcoal on the pharmacokinetics of moxifloxacin following intravenous and oral administration of a 400 mg single dose to healthy males. Br J Clin Pharmacol 2005;59:536-41.
31. Andersson DI, Hughes D. Microbiological effects of sublethal levels of antibiotics. Nat Rev Microbiol 2014;12:465-78.
32. Fantin B, Duval X, Massias L, et al. Ciprofloxacin dosage and emergence of resistance in human commensal bacteria. J Infect Dis 2009;200:390-8.
33. Burdet C, Sayah-Jeanne S, Nguyen TT, et al. Protection of hamsters from mortality by reducing fecal moxifloxacin concentration with DAV131A in a model of moxifloxacin- induced Clostridium difficile colitis. Antimicrob Agents Chemother 2017;61:e00543-17.